Xeris Biopharma Files 8-K on Operations & Financials
Ticker: XERS · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1867096
| Field | Detail |
|---|---|
| Company | Xeris Biopharma Holdings, Inc. (XERS) |
| Form Type | 8-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K, corporate-update
TL;DR
**Xeris Biopharma just dropped an 8-K on its financials, signaling an update on company performance.**
AI Summary
Xeris Biopharma Holdings, Inc. filed an 8-K on January 4, 2024, to report on its results of operations and financial condition. This filing, under SEC File Number 001-40880, indicates that the company is providing an update on its financial performance. For investors, this matters because it offers a timely glimpse into the company's health and operational efficiency, which can influence stock valuation and future investment decisions.
Why It Matters
This filing provides investors with current information on Xeris Biopharma's financial health, which is crucial for evaluating the company's performance and making informed investment decisions.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information, not indicating any immediate new risks or significant changes.
Analyst Insight
Investors should review the detailed financial statements and results of operations once they are made available to understand the company's current performance and future outlook.
Key Players & Entities
- Xeris Biopharma Holdings, Inc. (company) — the registrant filing the 8-K
- January 4, 2024 (date) — date of earliest event reported and filing date
- 001-40880 (string) — Commission File Number
- Delaware (string) — state of incorporation
- XERS (string) — trading symbol for Common Stock
- The Nasdaq Global Select Market (string) — exchange where Common Stock is registered
FAQ
What is the purpose of Xeris Biopharma Holdings, Inc.'s 8-K filing dated January 4, 2024?
The 8-K filing by Xeris Biopharma Holdings, Inc. on January 4, 2024, is to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as per the 'ITEM INFORMATION' section of the filing.
What is the trading symbol and the exchange where Xeris Biopharma's common stock is registered?
The trading symbol for Xeris Biopharma Holdings, Inc.'s Common Stock, par value $0.0001 per share, is XERS, and it is registered on The Nasdaq Global Select Market, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the business address and phone number of Xeris Biopharma Holdings, Inc.?
The business address of Xeris Biopharma Holdings, Inc. is 1375 West Fulton Street, Suite 1300, Chicago, Illinois 60607, and their telephone number is (844) 445-5704, according to the filing's cover page.
Is Xeris Biopharma Holdings, Inc. considered an emerging growth company?
Yes, Xeris Biopharma Holdings, Inc. indicates with a checkmark that it is an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
What is the Commission File Number for Xeris Biopharma Holdings, Inc.?
The Commission File Number for Xeris Biopharma Holdings, Inc. is 001-40880, as specified on the cover page of the 8-K filing.
Filing Stats: 445 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-01-04 07:09:00
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share XERS The Nasdaq Global Select
Filing Documents
- xers-20240104.htm (8-K) — 27KB
- pressreleaseissuedbyxerisb.htm (EX-99.1) — 11KB
- image_0a.jpg (GRAPHIC) — 18KB
- 0001867096-24-000003.txt ( ) — 220KB
- xers-20240104.xsd (EX-101.SCH) — 2KB
- xers-20240104_def.xml (EX-101.DEF) — 15KB
- xers-20240104_lab.xml (EX-101.LAB) — 28KB
- xers-20240104_pre.xml (EX-101.PRE) — 15KB
- xers-20240104_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 4, 2024, Xeris Biopharma Holdings, Inc. (the "Company") issued a press release announcing certain preliminary results for the year ended December 31, 2023. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press release issued by Xeris Biopharma Holdings, Inc. dated January 4 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 4, 2024 Xeris Biopharma Holdings, Inc. By: /s/ Steven M. Pieper Name: Steven M. Pieper Title: Chief Financial Officer